New Amsterdam Pharma

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well-tolerated.

NewAmsterdam Pharma seeks to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor in patients at risk of cardiovascular disease, for whom existing therapies are not sufficiently effective or well-tolerated. Obicetrapib is also being investigated as a potential treatment for Alzheimer’s disease.